T lymphocyte proliferation and survival pathways

T lymphocyte proliferation and survival pathways are the coordinated signaling networks that dictate the magnitude and duration of the adaptive immune response. These pathways are primarily triggered by the engagement of the T-cell receptor (TCR) with antigen-MHC complexes, which initiates a cascade of tyrosine phosphorylation events involving Lck and ZAP-70 (Smith-Garvin et al., 2009). Co-stimulatory signals, most notably through CD28, are required to amplify these signals and activate the PI3K/Akt/mTOR and NF-kB pathways, which promote metabolic reprogramming and the expression of anti-apoptotic proteins like Bcl-2 (Frauwirth & Thompson, 2002). Additionally, cytokines such as Interleukin-2 (IL-2) signal through the JAK/STAT pathway to drive robust clonal expansion and maintain the survival of activated T cells (Rochman et al., 2009). Dysregulation of these pathways is a hallmark of many diseases; for instance, excessive signaling contributes to autoimmune disorders and graft-versus-host disease, while impaired signaling or 'exhaustion' is often observed in chronic infections and cancer (Wherry & Kurachi, 2015). Consequently, these pathways are major therapeutic targets, with drugs ranging from calcineurin inhibitors like cyclosporine to modern immune checkpoint inhibitors that modulate survival signals to enhance anti-tumor activity (Sharpe & Pauken, 2018).

Other names

T-cell activation and survival signalingT-cell proliferation pathwaysT-lymphocyte signaling network

Modulation of T-cell activation and longevity through inhibition of intracellular signaling enzymes (e.g., calcineurin, mTOR, JAKs), blockade of cell-surface co-stimulatory receptors, or modulation of inhibitory checkpoint receptors.